AAOI vs PEGA

AAOI's deterministic health scores are severely compromised: the Piotroski F-Score of 0/9 signals extreme financial distress, with no positive indicators in profitability, leverage, or cash flow. The Altman Z-Score is unavailable, but the company's negative ROE (-7.94%), negative profit margins (-8.39%), and persistent losses despite 33.9% revenue growth indicate deep operational inefficiency. While the stock has delivered extraordinary price appreciation (510% in 1Y), this is not supported by fundamentals, and the valuation (P/E 30.28, Price/Sales 15.97) reflects a premium driven by speculative momentum rather than intrinsic value. Insider selling of $23.77M in the last 6 months further undermines confidence, signaling potential misalignment with public investors.

PEGA exhibits strong fundamental health with a Piotroski F-Score of 8/9 and an exceptional ROE of 57.32%, indicating efficient internal operations and a clean balance sheet. While the current price of $43.80 sits well below the growth-based intrinsic value of $62.83 and analyst targets, it is significantly above the defensive Graham Number of $14.88. The primary conflict lies between stellar profitability/health and anemic revenue growth (2.70%), coupled with bearish insider activity and a negative technical trend. The overall outlook is tempered by significant legal risks associated with Appian Corp.